stoxline Quote Chart Rank Option Currency Glossary
  
Arcus Biosciences, Inc. (RCUS)
15.99  -0.21 (-1.3%)    06-18 16:00
Open: 16.2
High: 16.2
Volume: 980,877
  
Pre. Close: 16.2
Low: 15.35
Market Cap: 1,454(M)
Technical analysis
2024-06-18 4:48:29 PM
Short term     
Mid term     
Targets 6-month :  19.59 1-year :  21.1
Resists First :  16.77 Second :  18.06
Pivot price 15.89
Supports First :  14.68 Second :  12.22
MAs MA(5) :  16.39 MA(20) :  16.02
MA(100) :  16.68 MA(250) :  17.48
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  66.8 D(3) :  72.5
RSI RSI(14): 48.5
52-week High :  25.46 Low :  12.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RCUS ] has closed below upper band by 45.8%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.23 - 16.33 16.33 - 16.4
Low: 15.12 - 15.25 15.25 - 15.34
Close: 15.82 - 16.01 16.01 - 16.15
Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Headline News

Mon, 17 Jun 2024
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - MarketBeat

Mon, 17 Jun 2024
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo News Malaysia

Sat, 15 Jun 2024
Octagon Capital Advisors LP Sells 100,000 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat

Sat, 15 Jun 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Stake Reduced by Octagon Capital Advisors LP - Defense World

Fri, 14 Jun 2024
Arcus Biosciences (NYSE:RCUS) Trading 7.5% Higher - MarketBeat

Thu, 13 Jun 2024
Arcus Biosciences Breaks Above 200-Day Moving Average - Bullish for RCUS - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 91 (M)
Shares Float 54 (M)
Held by Insiders 40.8 (%)
Held by Institutions 59.7 (%)
Shares Short 7,540 (K)
Shares Short P.Month 6,840 (K)
Stock Financials
EPS -3.11
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.78
Profit Margin -97.5 %
Operating Margin 2.7 %
Return on Assets (ttm) -12.3 %
Return on Equity (ttm) -35.4 %
Qtrly Rev. Growth 480 %
Gross Profit (p.s.) 0
Sales Per Share 2.6
EBITDA (p.s.) -2.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -210 (M)
Levered Free Cash Flow -94 (M)
Stock Valuations
PE Ratio -5.15
PEG Ratio 0
Price to Book value 2.05
Price to Sales 6.13
Price to Cash Flow -6.93
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android